Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Review, H2 2016', provides in depth analysis on Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted pipeline therapeutics. 

The report provides comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) 
- The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Overview 6
Therapeutics Development 7
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Products under Development by Stage of Development 7
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Products under Development by Therapy Area 8
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Products under Development by Indication 9
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Products under Development by Companies 12
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development 21
Ipsen S.A. 21
Mallinckrodt Plc 22
Pfizer Inc. 23
Retrophin Inc. 24
XOMA Corporation 25
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles 26
AQB-565 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BIM-23B065 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
corticotropin - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
cosyntropin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing's Disease - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Projects 33
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products 34
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Featured News & Press Releases 35
Jul 05, 2016: Health Care Resource Use and Costs of H.P. Acthar Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse 35
Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus 36
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 38
Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus 38
Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 40
Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 40
Mar 27, 2015: Positive Outcomes With H.P. Acthar Gel In Proteinuria In Nephrotic Syndrome Reported At National Kidney Foundation Spring Congress 41
Jan 06, 2015: BioSim Pharmaceuticals to meet with Industry during JP Morgan Healthcare Conference 42
May 05, 2014: Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus 42
Apr 21, 2014: Clinical Trial Results Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy 43
Oct 22, 2013: Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome 44
Jul 24, 2013: Questcor to Commence Phase 2 Study of Acthar for ALS 44
Jul 11, 2013: Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis 45
Jun 14, 2012: Questcor Pharma Announces Initial Commercialization Plans For Acthar Rheumatology Indications 46
Nov 10, 2011: New Research Suggests Questcor's Acthar Reduces Proteinuria In Idiopathic Membranous Nephropathy In Part Through Suppression Of Anti-PLA2R Antibodies 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Ipsen S.A., H2 2016 21
Pipeline by Mallinckrodt Plc, H2 2016 22
Pipeline by Pfizer Inc., H2 2016 23
Pipeline by Retrophin Inc., H2 2016 24
Pipeline by XOMA Corporation, H2 2016 25
Dormant Projects, H2 2016 33
Discontinued Products, H2 2016 34